A detailed history of Black Rock Inc. transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,158,661 shares of ABOS stock, worth $5.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,158,661
Previous 189,697 1037.95%
Holding current value
$5.46 Million
Previous $768,000 580.08%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.14 - $4.01 $4.21 Million - $7.9 Million
1,968,964 Added 1037.95%
2,158,661 $5.22 Million
Q1 2024

May 10, 2024

SELL
$2.97 - $4.64 $173,442 - $270,966
-58,398 Reduced 23.54%
189,697 $768,000
Q4 2023

Feb 13, 2024

SELL
$1.86 - $4.48 $623,693 - $1.5 Million
-335,319 Reduced 57.48%
248,095 $952,000
Q3 2023

Nov 13, 2023

BUY
$4.15 - $9.72 $415,373 - $972,874
100,090 Added 20.71%
583,414 $2.42 Million
Q2 2023

Aug 11, 2023

SELL
$3.59 - $6.59 $676,022 - $1.24 Million
-188,307 Reduced 28.04%
483,324 $2.32 Million
Q1 2023

May 12, 2023

SELL
$3.75 - $6.65 $1.77 Million - $3.15 Million
-473,056 Reduced 41.33%
671,631 $2.73 Million
Q4 2022

Feb 13, 2023

BUY
$4.81 - $10.17 $142,664 - $301,642
29,660 Added 2.66%
1,144,687 $6.18 Million
Q3 2022

Nov 14, 2022

SELL
$4.44 - $10.48 $7.01 Million - $16.5 Million
-1,578,284 Reduced 58.6%
1,115,027 $11.2 Million
Q2 2022

Aug 12, 2022

SELL
$3.08 - $4.88 $3.51 Million - $5.55 Million
-1,138,010 Reduced 29.7%
2,693,311 $12.7 Million
Q1 2022

May 12, 2022

BUY
$3.91 - $6.73 $2.82 Million - $4.86 Million
721,651 Added 23.21%
3,831,321 $15 Million
Q4 2021

Feb 10, 2022

BUY
$6.54 - $15.31 $1.58 Million - $3.69 Million
240,879 Added 8.4%
3,109,670 $21 Million
Q3 2021

Nov 09, 2021

BUY
$14.5 - $20.28 $41.6 Million - $58.2 Million
2,868,791 New
2,868,791 $42.6 Million

Others Institutions Holding ABOS

About Acumen Pharmaceuticals, Inc.


  • Ticker ABOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,503,100
  • Market Cap $102M
  • Description
  • Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...
More about ABOS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.